Vacuum Gas/Solid<i>N</i>-Chlorination: Preparative Scale Synthesis of Volatile<i>N</i>-Chloramines
作者:J. C. Guillemin、J. M. Denis
DOI:10.1055/s-1985-31450
日期:——
A simple method for the preparative scale synthesis of volatile chloramines free from impurities starting from the corresponding primary or secondary amine using N-chlorosuccinimide as chlorinating agent is described.
A new method for the direct one-pot oxidative amidation between methylarenes and amines catalyzed by copper has been developed. This method integrates methylarene oxidation and amide bond formation, which are usually accomplished separately, into a single operation. In addition, the reaction provides a relatively high yield and has a wide substrate scope. Moreover, the starting reagents are abundant
amidation between methylarenes with amines in a two-step continuous flow system. This method integrates methylarene oxidation and amide formation into a single operation which is usually accomplished separately. Oxidation with tert-butyl hydroperoxide (TBHP) as “green” oxidant, the synthesis of amides under mild reaction conditions in continuous flow system and the utilization of methylarenes as starting
Copper-catalyzed one-pot oxidative amidation of both aliphatic and aromatic alcohols with N-chloramines, prepared in situ from many types of primary and secondary amines, to form amides under mild conditions.
Malonic acid derivatives, processes for their preparation, for their use and pharmaceutical compositions containing them
申请人:Aventis Pharma Deutschland GmbH
公开号:US06395737B1
公开(公告)日:2002-05-28
New compounds for the inhibition of blood clotting proteins, and more particularly, to malonic acid derivatives of the formula I,
wherein R(1), R(2), R(3), R(4), R(5), and R(6) have the meanings indicated in the claims. The compounds of formula I are inhibitors of the blood clotting enzyme factor Xa. Processes for the preparation of the compounds of formula I, methods of inhibiting factor Xa activity and of inhibiting blood clotting, use of the compounds of formula I in the treatment and prophylaxis of diseases, which can be treated or prevented by the inhibition of factor Xa activity such as thromboembolic diseases, and use of the compounds of formula I in the preparation of medicaments to be applied in such diseases. Compositions containing a compound of formula I in admixture or otherwise in association with an inert carrier, in particular pharmaceutical compositions containing a compound of formula I together with pharmaceutically acceptable carrier substances and auxiliary substances.